Nosopharm brings antibiotic one step closer to clinical development

Nosopharm brings antibiotic one step closer to clinical development

By, Admin 10 June 2025

Overview

Biotechnology company Nosopharm has reported positive toxicology results for its first-in-class antibiotic for the treatment of multidrug-resistant hospital-acquired infections.

Novel antibiotics: NOSO-502

  • The company’s NOSO-502 is the first clinical candidate in the new class of antibiotics called Odilorhabdins and is being developed alongside GNA NOW, a European Consortium funded by the Innovative Medicines Initiative 2 (IMI2).
  • Discovered by Nosopharm from a Xenorhabdus bacteria, NOSO-502 is intended for the treatment of the main hospital-acquired infections caused by the multidrug-resistant Enterobacterales: Escherichia coli, Klebsiella pneumoniae and Enterobacter spp.
  • Now, Nosopharm has reported positive GLP toxicology studies combined with other results in clinical microbiology, efficacy and pharmacokinetics/pharmacodynamics studies. 
  • Nosopharm will now prepare a Clinical Trial Authorisation application, which if granted, will enable the entry of NOSO-502 into first-in-human clinical studies.

GNA NOW Consortium Tackles Antimicrobial Resistance in Gram-Negative Bacteria

  • Multidrug-resistant Gram-negative pathogens contributed to 59% of 1.27 million deaths in 2019.
  • Antimicrobial resistance (AMR) is a major global health threat, with Gram-negative bacteria posing the greatest danger to patients.
  • The pipeline for therapies targeting AMR in Gram-negative bacteria is currently lacking.
  • The GNA NOW Consortium, led by Evotec as an EFPIA representative, is working to develop new Gram-negative antibiotics.
  • Their goal is to advance new drug classes from lead optimization to Phase I clinical trials.

Recommendation news for NOSO-502 programme

  • The NOSO-502 programme received a unanimous recommendation from the internal and external experts of the GNA NOW Consortium to start preparing for clinical trials. 
  • This is of particular importance as novel classes of antibiotics with efficacy against the WHO critical priority Gram-negative pathogens are very rare. 
  • No novel class of antibiotics with efficacy against these pathogens has been introduced into clinical use for more than 40 years.

Official comments

  • Commenting on this milestone, Lynn Silver, an expert in antibacterial drug discovery and preclinical development, and a member of the general project review group for IMI said: “The positive results of the NOSO-502 programme demonstrate the importance of discovery and development partnerships like the GNA NOW Consortium. It proves that this kind of work can be done collaboratively by partners from academia, industry and big pharma. Together, it is possible to achieve positive results during the notoriously challenging early stages of antibiotic development.”
  • The results of these GLP toxicology studies are very encouraging. Combined with the other results acquired with the GNA NOW Consortium, they allow us to carry out further development of the program to Phase 1, provided we receive regulatory authorisation. This is an important milestone. These results demonstrate the quality and the innovativeness of NOSO-502, which has the potential to treat life-threatening multidrug-resistant infections,” said Philippe Villain-Guillot, co-founder and CEO of Nosopharm.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!